RMD Open (Apr 2023)

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases

  • ,
  • Tobias Alexander,
  • Hendrik Schulze-Koops,
  • Ulf Müller-Ladner,
  • Rebecca Fischer-Betz,
  • Martin Aringer,
  • Rieke Alten,
  • Petra Saar,
  • Tim Schmeiser,
  • Marina Backhaus,
  • Stephanie Finzel,
  • Cornelia Glaser,
  • Hildrun Haibel,
  • Hanns-Martin Lorenz,
  • Gamal Chehab,
  • Christof Specker,
  • Reinhard E Voll,
  • Anja Strangfeld,
  • Norbert Blank,
  • Matthias Braun,
  • Alexander Pfeil,
  • Rebecca Hasseli,
  • Andreas Krause,
  • Anne Constanze Regierer,
  • Peer Aries,
  • Ioana Andreica,
  • Jacqueline Detert,
  • Elvira Decker,
  • Urs Hartmann,
  • Joerg Henes,
  • Kirsten de Groot,
  • JOACHIM GEORGI,
  • Hans Bastian,
  • Christoph Fiehn,
  • Martin Feuchtenberger,
  • Martin Fleck,
  • Christian Blum,
  • Mathias Grunke,
  • Martin Bohl-Bühler,
  • Georg Gauler,
  • Bimba Franziska Hoyer,
  • Guido Hoese,
  • Janine Günther,
  • Matthias Braunisch,
  • Jutta G. Richter,
  • Sabine Reckert,
  • Anett Gräßler,
  • Andreas Kapelle,
  • Silke Osiek,
  • Anna Knothe,
  • Jan Brandt-Jürgens,
  • Anja Maltzahn,
  • Fredrik Albach,
  • Annette Alberding,
  • Susanne Aman,
  • Christopher Amberger,
  • Michaela Amberger,
  • Bianka Andermann,
  • Nils Anders,
  • Jan Andresen,
  • Nikolaos Andriopoulos,
  • Elizabeth Arauj,
  • Uta Arndt,
  • Sarah Avemarg,
  • Christoph Baerwald,
  • Erich Bärlin,
  • Nora Bartholomä,
  • Michael Bäuerle,
  • Jutta Bauhammer,
  • Christine Baumann,
  • Klaus Becker,
  • Heidemarie Becker,
  • Michaela Bellm,
  • Sylvia Berger,
  • Andrea Berghofen,
  • Gerhard Birkner,
  • Daniel Blendea,
  • Hans Bloching,
  • Sebastian Blötz,
  • Stephanie Boeddeker,
  • Susanne Bogner,
  • Lara Bohnen,
  • Ilka Bösenberg,
  • Nicole Böttcher,
  • Diana Braun,
  • Jan Philipp Bremer,
  • Matthias Broll,
  • Andreas Bruckner,
  • Veronika Brumberger,
  • Martin Brzank,
  • Sahra Büllesfeld,
  • Sandra Burger,
  • Michaela Christenn,
  • Anne Claußnitzer,
  • Frank Demtröder,
  • Rainer Dörfler,
  • Elke Drexler,
  • Valeria Dudics,
  • Edmund Edelmann,
  • Roman Eder,
  • Christina Eisterhues,
  • Joachim Michael Engel,
  • Brigitte Erbslöh-Möller,
  • Miriam Feine,
  • Samantha Ferdinan,
  • Claudia Franke,
  • Stefanie Freudenberg,
  • Christian Fräbel,
  • Petra Fuchs,
  • Regina Gaissmaier,
  • Ino Gao,
  • Oliver Gardt,
  • Katrin Geißler,
  • Karolina Gente,
  • Jasmin Gilly,
  • Yannik Gkanatsas,
  • Agnes Gniezinski- Schwister,
  • Rahel Gold,
  • Norman Görl,
  • Ralf Görlitz,
  • Karl-Heinz Göttl,
  • Beate Göttle,
  • Ricardo Grieshaber Bouyer,
  • Gisela Grothues,
  • Florian Günther,
  • Mirjam Haag,
  • Linda Haas,
  • Anna Haas-Wöhrle,
  • Denitsa Hadjiski,
  • Till Hallmann-Böhm,
  • Peter Härle,
  • Charlotte Hasenkamp,
  • Maura-Maria Hauf,
  • Matthias Hauser

DOI
https://doi.org/10.1136/rmdopen-2023-002998
Journal volume & issue
Vol. 9, no. 2

Abstract

Read online

Objective To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs).Methods Data from the physician-reported German COVID-19-IRD registry collected between February 2021 and July 2022 were analysed. SARS-CoV-2 cases were stratified according to patients’ vaccination status as being not vaccinated, double-vaccinated or triple-vaccinated prior to SARS-CoV-2 infection and descriptively compared. Independent associations between demographic and disease features and outcome of breakthrough infections were estimated by multivariable logistic regression.Results In total, 2314 cases were included in the analysis (unvaccinated n=923, double-vaccinated n=551, triple-vaccinated n=803, quadruple-vaccinated n=37). SARS-CoV-2 infections occurred after a median of 151 (range 14–347) days in patients being double-vaccinated, and after 88 (range 14–270) days in those with a third vaccination. Hospitalisation was required in 15% of unvaccinated, 8% of double-vaccinated and 3% of triple-vaccinated/quadruple-vaccinated patients (p<0.001). Mortality was 2% in unvaccinated, 1.8% in the double-vaccinated and 0.6% in triple-vaccinated patients. Compared with unvaccinated patients, double-vaccinated (OR 0.43, 95% CI 0.29 to 0.62) and triple-vaccinated (OR 0.13, 95% CI 0.08 to 0.21) patients showed a significant lower risk of COVID-19-related hospitalisation. Using multivariable analysis, the third vaccination was significantly associated with a lower risk for COVID-19-related death (OR 0.26; 95% CI 0.01 to 0.73).Conclusions Our cross-sectional data of COVID-19 infections in patients with IRD showed a significant reduction of hospitalisation due to infection in double-vaccinated or triple-vaccinated patients compared with those without vaccination and even a significant reduction of COVID-19-related deaths in triple-vaccinated patients. These data strongly support the beneficial effect of COVID-19 vaccination in patients with IRD.Trial registration number EuDRACT 2020-001958-21.